MBRX

Moleculin Biotech, Inc. (MBRX) 10Y Growth Potential Analysis (2026)

Invetso Score: 1/10 — Weak · Last Updated: 2026-09-01

Overall Score

Revenue Growth

No revenue growth evidence in the provided TTM metrics; price-to-sales is 0 and revenue per share is 0, indicating no meaningful sales base to scale.

Profitability

TTM margins are all 0 and returns remain deeply negative, with ROA at -1.44, ROE at -8.17, and ROIC at -2.42.

Operating cash flow and free cash flow are negative on a per-share basis, reinforcing the lack of earnings power.

Financial Health

Liquidity is strained with a current ratio of 0.94 and negative working capital of -590k.

Leverage is low in absolute terms, but the company still shows negative solvency metrics and weak cash-flow coverage.

Reinvestment Moat

There is no evidence of durable reinvestment efficiency or moat-like economics, as operating margins, asset turnover, and capital returns are all near zero or negative.

High intangible asset concentration (intangibles to total assets at 0.53) does not currently translate into measurable operating advantage.

Valuation

The stock screens as optically cheap on several ratios, including price-to-book at 0.35 and enterprise value to EBITDA near 0.10.

However, the valuation is offset by persistent losses and negative cash generation, making the low multiples difficult to rely on for a 10-year growth case.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Moleculin Biotech, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →